ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0502

Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Abstract Number: 0503

Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis
Abstract Number: 0504

Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis
Abstract Number: 0505

Use of Upadacitinib in Real-World Clinical Practice: Patient Characteristics and Glucocorticoid-Sparing Effect
Abstract Number: 0506

Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren’s Disease Using High-content Human Proteome Arrays
Abstract Number: 0507

Diagnostic performance of the lacrimal and salivary gland ultrasound in patients with primary Sjogren’s disease of recent onset versus sicca controls.
Abstract Number: 0508

Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
Abstract Number: 0509

Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
Abstract Number: 0510

A risk estimation tool for clinical practice to improve early ILD detection in Sjögren Disease
Abstract Number: 0511

Submandibular Gland Ratio Stratifies Salivary Function and Reveals a Senescence Peak in Anti-SSA Positive Sjögren’s Syndrome
Abstract Number: 0512

Dry Eye Disease Severity and Salivary Gland Biopsy in Patients with Primary Sjögren’s Syndrome
Abstract Number: 0513

Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
Abstract Number: 0514

Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
Abstract Number: 0515

Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
Abstract Number: 0516

Association between anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies and lymphoma in primary Sjögren Disease (SD)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].